This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ampio Insiders, Aided by PR Blitz, Soon Free to Sell Millions of Shares

Stocks in this article: AMPE

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

GREENWOOD VILLAGE, Col. ( TheStreet) -- A recent promotional blitz that has sent shares of Ampio Pharmaceuticals (AMPIO) soaring appears to be timed well to coincide with the expiration of lockups that will allow company's executives and insiders to sell millions of shares of stock for big profits.

The expiration of these these stock-sale lockups at the end of June and in two weeks on July 15 cover nearly one-third of Ampio's outstanding shares.

My best guess: Ampio is pumping out press releases at a rapid clip to promote itself -- and compensating outsider writers who publish glowing articles -- just so retail investors and momentum traders will buy stock at rapidly escalating prices from insiders all too willing to sell. Ampio has also tried to push the company's stock price higher by urging shareholders to stop their brokers from lending out Ampio shares for short sales.

Ampio shares were up 14% to $5.78 Monday, having already in value over the past two months. Eight Ampio-issued press releases since late April have helped, as have 17 articles published by Seeking Alpha, all heaping praise on the company.

One author is responsible for seven of the Ampio articles published on Seeking Alpha despite admitting that Ampio recently paid for his airfare to visit the company’s headquarters and that he wishes to be hired as an Ampio spokesperson.

As long as Ampio shares keep moving higher, investors don't seem to care that the company's drug pipeline is highly speculative and already showing signs of clinical failure. This party may end, however, once Ampio insiders start selling stock by the truckload.

On July 15, Ampio executives, directors and other insiders will be free to sell 8.25 million shares of company stock, according to the company's regulatory filings. These shares have been largely locked up since last year.

On Saturday, June 30, a separate lock-up agreement covering 8.4 million shares of Ampio controlled by shareholders of owned by DMI BioSciences also expired, according to regulatory filings.

Ampio acquired DMI BioSciences last year in an all-stock deal that brought with it the experimental premature ejaculation drug Zertane.

Ampio's regulatory filings do not make it clear how much, if any, overlap exists between the shares covered by the two expiring lock up periods. Regardless, within two weeks, Ampio insiders will be free to sell millions of shares of stock to retail investors at inflated prices.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs